Hikma Pharmaceuticals Plc Additional Listing (2909M)
January 10 2023 - 9:42AM
UK Regulatory
TIDMHIK
RNS Number : 2909M
Hikma Pharmaceuticals Plc
10 January 2023
Block Listing of Shares
Hikma Pharmaceuticals PLC
LONDON, 10 January 2023 - The Board of Hikma Pharmaceuticals PLC
("Hikma") (LSE: HIK) (LEI: 549300BNS685UXH4JI75) (NASDAQ: HIK),
announces that it has made a block listing application to the
Financial Conduct Authority and the London Stock Exchange plc for a
total of 1,200,000 ordinary shares of 10p each in the capital of
the Company to be admitted to the Official List of the UK Listing
Authority. It is expected that admission will be granted on 12
January 2023 .
The shares, when issued, will be issued fully paid and rank pari
passu in all respects with the existing issued ordinary shares of
the Company. The shares will be issued pursuant to the vesting of
shares under the Hikma Pharmaceuticals PLC 2018 Management
Incentive Plan and 2014 Executive Incentive Plan (the "Plans") .
Participants in the Plans have or will become entitled to these
shares following the vesting of the shares.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Helen Middlemist
Deputy Company Secretary +44 (0) 2073992760
About Hikma
Hikma helps put better health within reach every day for
millions of people around the world. For more than 40 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across North America, the Middle East
and North Africa (MENA) and Europe, and we use our unique insight
and expertise to transform cutting-edge science into innovative
solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively
and acting practically, we provide them with a broad range of
branded and non-branded generic medicines. Together, our 8,700
colleagues are helping to shape a healthier world that enriches all
our communities. We are a leading licensing partner, and through
our venture capital arm, are helping bring innovative health
technologies to people around the world. For more information,
please visit www.hikma.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ALSGPUGCGUPWGAU
(END) Dow Jones Newswires
January 10, 2023 10:42 ET (15:42 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024